Aperio Group’s Impax Laboratories, Inc. IPXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-54,530
| Closed | -$1.06M | – | 2314 |
|
|
2018
Q1 | $1.06M | Sell |
54,530
-2,365
| -4% | -$46.4K | 0.01% | 1279 |
|
|
2017
Q4 | $947K | Sell |
56,895
-176
| -0.3% | -$3.23K | ﹤0.01% | 1330 |
|
|
2017
Q3 | $1.16M | Buy |
57,071
+1,785
| +3% | +$34.1K | 0.01% | 1189 |
|
|
2017
Q2 | $890K | Buy |
55,286
+26,366
| +91% | +$389K | 0.01% | 1299 |
|
|
2017
Q1 | $366K | Buy |
28,920
+11,350
| +65% | +$137K | ﹤0.01% | 1728 |
|
|
2016
Q4 | $233K | Buy |
17,570
+2,794
| +19% | +$47.8K | ﹤0.01% | 1922 |
|
|
2016
Q3 | $350K | Buy |
14,776
+2,608
| +21% | +$70.1K | ﹤0.01% | 1644 |
|
|
2016
Q2 | $351K | Sell |
12,168
-1,903
| -14% | -$62K | ﹤0.01% | 1591 |
|
|
2016
Q1 | $451K | Buy |
14,071
+1,537
| +12% | +$54K | ﹤0.01% | 1419 |
|
|
2015
Q4 | $536K | Buy |
12,534
+1,963
| +19% | +$78.4K | ﹤0.01% | 1302 |
|
|
2015
Q3 | $372K | Buy |
10,571
+82
| +0.8% | +$3.69K | ﹤0.01% | 1451 |
|
|
2015
Q2 | $482K | Buy |
10,489
+751
| +8% | +$35.6K | 0.01% | 1345 |
|
|
2015
Q1 | $456K | Buy |
9,738
+2,243
| +30% | +$89.3K | 0.01% | 1327 |
|
|
2014
Q4 | $237K | Buy |
+7,495
| New | +$219K | ﹤0.01% | 1647 |
|
Aperio Group's IPXL Position: Q2 2018 in Review
Aperio Group sold out of Impax Laboratories, Inc. (IPXL) in Q2 2018, closing a stake of 54,530 shares — an estimated $1.06M sold.
Aperio Group first reported a position in IPXL in Q4 2014 and held it in 14 quarters. The position peaked at $1.16M in Q3 2017. 1 fund tracked by Wall St. Rank holds IPXL as of Q2 2018.
- Aperio Group reported no remaining Impax Laboratories, Inc. position as of Q2 2018 after selling out during the quarter.
- Aperio Group sold 54,530 Impax Laboratories, Inc. shares in Q2 2018, an estimated $1.06M.
- Aperio Group first reported a position in Impax Laboratories, Inc. in Q4 2014 and held it in 14 quarters.
- Aperio Group's Impax Laboratories, Inc. position peaked at $1.16M in Q3 2017.
- 1 fund tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2018.
Based on Aperio Group's 13F filing for Q2 2018, filed 30 Jul 2018.